A case of Anti-Hu and Anti-Zic4 paraneoplastic cerebellar degeneration in a patient with stage IV adenocarcinoma of Müllerian origin

IF 1.2 Q3 OBSTETRICS & GYNECOLOGY
Saad Rashid , Suneha Pocha , Nada Saleh , Erin Ozminkowski , Vijayta Geeta Bansal , Vibhav Bansal
{"title":"A case of Anti-Hu and Anti-Zic4 paraneoplastic cerebellar degeneration in a patient with stage IV adenocarcinoma of Müllerian origin","authors":"Saad Rashid ,&nbsp;Suneha Pocha ,&nbsp;Nada Saleh ,&nbsp;Erin Ozminkowski ,&nbsp;Vijayta Geeta Bansal ,&nbsp;Vibhav Bansal","doi":"10.1016/j.gore.2025.101804","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Paraneoplastic cerebellar degeneration (PCD) is a rare neurological complication of malignancies, resulting from autoimmune responses targeting antigens shared by neurons and tumors. It is characterized by progressive cerebellar dysfunction, including ataxia and dysarthria, and is associated with anti-onconeuronal antibodies such as Anti-Yo and Anti-Hu. While most cases of Anti-Hu-associated PCD occur in patients with small cell lung cancer, their association with gynecologic malignancies is exceedingly rare. This is the first reported case in the literature of a patient with adenocarcinoma of Müllerian origin complicated by Anti-Hu PCD.</div></div><div><h3>Case</h3><div>We present the case of a 73-year-old female with stage IV adenocarcinoma of Müllerian origin who presented with worsening ataxia and dysarthria after undergoing outpatient chemoimmunotherapy to treat her gynecologic malignancy. CT and MRI Brain imaging revealed nonspecific findings, but cerebrospinal fluid (CSF) analysis revealed the presence of positive anti-Hu and anti-Zic4 antibodies, consistent with a diagnosis of PCD. Despite treatment with high-dose intravenous corticosteroids and plasmapheresis in the acute setting, the patient displayed minimal improvement and continued to experience persistent neurological impairment.</div></div><div><h3>Conclusion</h3><div>Despite advancements in diagnostic criteria and the availability of multiple types of therapies, outcomes for PCD remain poor. This is especially notable for cases associated with Anti-Hu antibodies. This case highlights the importance of considering PCD in the differential diagnosis of patients with malignancies and unexplained neurological symptoms. Furthermore, it highlights the critical need for continued research to refine diagnostic methods and develop more effective, evidence-based treatment strategies to improve outcomes.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"60 ","pages":"Article 101804"},"PeriodicalIF":1.2000,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gynecologic Oncology Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2352578925001298","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

Paraneoplastic cerebellar degeneration (PCD) is a rare neurological complication of malignancies, resulting from autoimmune responses targeting antigens shared by neurons and tumors. It is characterized by progressive cerebellar dysfunction, including ataxia and dysarthria, and is associated with anti-onconeuronal antibodies such as Anti-Yo and Anti-Hu. While most cases of Anti-Hu-associated PCD occur in patients with small cell lung cancer, their association with gynecologic malignancies is exceedingly rare. This is the first reported case in the literature of a patient with adenocarcinoma of Müllerian origin complicated by Anti-Hu PCD.

Case

We present the case of a 73-year-old female with stage IV adenocarcinoma of Müllerian origin who presented with worsening ataxia and dysarthria after undergoing outpatient chemoimmunotherapy to treat her gynecologic malignancy. CT and MRI Brain imaging revealed nonspecific findings, but cerebrospinal fluid (CSF) analysis revealed the presence of positive anti-Hu and anti-Zic4 antibodies, consistent with a diagnosis of PCD. Despite treatment with high-dose intravenous corticosteroids and plasmapheresis in the acute setting, the patient displayed minimal improvement and continued to experience persistent neurological impairment.

Conclusion

Despite advancements in diagnostic criteria and the availability of multiple types of therapies, outcomes for PCD remain poor. This is especially notable for cases associated with Anti-Hu antibodies. This case highlights the importance of considering PCD in the differential diagnosis of patients with malignancies and unexplained neurological symptoms. Furthermore, it highlights the critical need for continued research to refine diagnostic methods and develop more effective, evidence-based treatment strategies to improve outcomes.
4期勒氏腺癌伴抗hu和抗zic4小脑变性1例
副肿瘤小脑变性(PCD)是一种罕见的恶性肿瘤神经系统并发症,由针对神经元和肿瘤共有抗原的自身免疫反应引起。它的特点是进行性小脑功能障碍,包括共济失调和构音障碍,并与抗肿瘤抗体如Anti-Yo和Anti-Hu相关。虽然大多数与抗胡相关的PCD发生在小细胞肺癌患者中,但它们与妇科恶性肿瘤的关联非常罕见。这是文献中第一例报道的勒氏腺癌合并抗- hu PCD的病例。病例:我们报告一位73岁的女性,患有勒氏起源的IV期腺癌,她在接受门诊化疗免疫治疗妇科恶性肿瘤后,表现为共济失调和构音障碍恶化。CT和MRI脑成像显示非特异性发现,但脑脊液(CSF)分析显示存在抗hu和抗zic4抗体阳性,与PCD的诊断一致。尽管在急性情况下进行了大剂量静脉注射皮质类固醇和血浆置换治疗,但患者的改善微乎其微,并继续经历持续的神经损伤。结论尽管诊断标准和多种治疗方法有所进步,但PCD的预后仍然很差。这对于与抗hu抗体相关的病例尤其值得注意。本病例强调了在恶性肿瘤和不明原因神经症状患者鉴别诊断中考虑PCD的重要性。此外,它强调了继续研究以改进诊断方法和制定更有效的循证治疗策略以改善结果的迫切需要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Gynecologic Oncology Reports
Gynecologic Oncology Reports OBSTETRICS & GYNECOLOGY-
CiteScore
2.00
自引率
0.00%
发文量
183
审稿时长
41 days
期刊介绍: Gynecologic Oncology Reports is an online-only, open access journal devoted to the rapid publication of narrative review articles, survey articles, case reports, case series, letters to the editor regarding previously published manuscripts and other short communications in the field of gynecologic oncology. The journal will consider papers that concern tumors of the female reproductive tract, with originality, quality, and clarity the chief criteria of acceptance.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信